The company brings experience and agility
to meet critical hospital pharmacy needs
ROSEMONT, Ill., May 1, 2024
/PRNewswire/ -- Long Grove Pharmaceuticals continues to meet the
critical care needs of hospital pharmacies with the launch of
Premix Vasopressin in its most commonly used concentrations.
Long Grove Pharmaceuticals will initially enter the market with
the following concentrations of Premix Vasopressin:
- 20 units/100 mL (0.2 units/mL) in 0.9% sodium chloride
- 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride
"We're focusing on the areas of greatest need in critical care,
and our launch of Premix Vasopressin demonstrates this commitment.
Our extensive hospital pharmacy and pharmaceutical industry
experience enables us to develop differentiated pharmaceuticals
designed to specifically meet key customer and patient needs," said
Peter Karas, Chief Commercial
Officer at Long Grove Pharmaceuticals.
Vasopressin in Sodium Chloride Injection is generally
used to increase blood pressure when other measures have
failed for patients in critical hypotensive shock. Hospital
pharmacies throughout the U.S. have a critical need for premix
vasopressin with a long shelf life. Long
Grove's new product offering will deliver immediate value to
hospital pharmacies and their patients.
Long Grove Pharmaceuticals introduced its first product to
customers in 2022. The company is improving the generic supply
chain by developing complex formulations, addressing manufacturing
challenges, and achieving regulatory approvals in difficult
environments.
"We believe that collaborative and reliable partnerships with
manufacturers, developers, suppliers, and customers are
essential for sustaining a healthy drug supply chain.," explained
Mr. Karas.
Premix Vasopressin ordering and contracting details will be
available soon. Please visit www.longgrovepharma.com for the latest
product availability information.
About Long Grove Pharmaceuticals
Long Grove
Pharmaceuticals, LLC was established in 2019 by Water Street
Healthcare Partners. The company is part of Capstone Development
Services Company, LLC, which has been developing products in
partnership with the world's premier pharmaceutical and medical
device organizations since 2013. Combining decades of
pharmaceutical and hospital leadership experience with a portfolio
of specialized, complex drug formulations, Long Grove
Pharmaceuticals is delivering differentiated products that increase
hospital pharmacy operational efficiency and help improve the
quality of patient care.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/long-grove-will-soon-offer-premix-vasopressin-to-help-relieve-stress-on-critical-care-302133317.html
SOURCE Water Street Healthcare Partners